Liau Gene 4
4 · Stoke Therapeutics, Inc. · Filed Oct 13, 2020
Insider Transaction Report
Form 4
Liau Gene
EVP Research & Preclinical Dev
Transactions
- Sale
Common Stock
2020-10-13$40.00/sh−1,649$65,960→ 13,500 total - Exercise/Conversion
Employee Stock Option (right to buy)
2020-10-13−1,649→ 132,417 totalExercise: $0.60Exp: 2028-04-02→ Common Stock (1,649 underlying) - Exercise/Conversion
Common Stock
2020-10-13$0.60/sh+1,649$989→ 15,149 total
Footnotes (2)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.